

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Town Health International Medical Group Limited
康健國際醫療集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 3886)

**RESIGNATION OF NON-EXECUTIVE DIRECTOR;
APPOINTMENT OF NON-EXECUTIVE DIRECTOR;
AND
CHANGE IN COMPOSITION OF BOARD COMMITTEES**

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board announces that Mr. Hou Jun has tendered his resignation as a non-executive Director with effect from 11 January 2024.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board announces that Ms. Zhang Leidi has been appointed as a non-executive Director with effect from 12 January 2024.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board announces that with effect from 12 January 2024:

- (i) Mr. Yu Xuezhong, an independent non-executive Director, has resigned as a member of the Audit Committee;
- (ii) Dr. Xu Weiguo, an independent non-executive Director, has resigned as a member of the Remuneration Committee;

- (iii) Mr. Liu Yang, a non-executive Director, has been appointed as a member of each of the Audit Committee and the Remuneration Committee;
- (iv) Mr. Chan Wai Kan, an independent non-executive Director, has been appointed as a member of the Remuneration Committee;
- (v) Mr. Cheung Ka Ming, an independent non-executive Director, has been appointed as a member of the Audit Committee; and
- (vi) Mr. Tsui Wing Cheong Sammy, an independent non-executive Director, has been appointed as a member of the Nomination Committee.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (“**Board**”) of directors (“**Directors**”) of Town Health International Medical Group Limited (“**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Hou Jun (“**Mr. Hou**”) has tendered his resignation as a non-executive Director with effect from 11 January 2024 as he would like to devote more time to focus on his other personal engagements.

Mr. Hou has confirmed that he does not have any disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (“**Shareholders**”).

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board announces that Ms. Zhang Leidi (“**Ms. Zhang**”) has been appointed as a non-executive Director with effect from 12 January 2024.

The biographical details of Ms. Zhang are set out below:

Ms. Zhang Leidi, aged 43. Ms. Zhang obtained a master’s degree in economics from Peking University in July 2003.

Ms. Zhang has over 20 years of experience in equity investment and project management. Ms. Zhang is currently the vice-president (presiding over the work) (副總經理(主持工作)) of China Life Private Equity Investment Company Limited (“**China Life Private Equity**”), and serves as a director and/or supervisor in several subsidiaries of China Life Private Equity. As at the date of this announcement, China Life Private Equity is a wholly-owned subsidiary of China Life Insurance (Group) Company (中國人壽保險(集團)公司), a substantial Shareholder (as defined under the Rules (“**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”)).

Ms. Zhang worked in Roland Berger Strategy Consultants from July 2003 to February 2010, where she successively worked as consultant, senior consultant and project manager. From March 2011 to September 2011, she worked as a part-time consultant in Roland Berger Strategy Consultants. From October 2011 to September 2016, Ms. Zhang worked in China Life Investment Holdings Co., Ltd. (國壽投資控股有限公司), where she successively worked as senior manager, investment director and senior investment director of the direct investment department. Since October 2016, Ms. Zhang has worked in China Life Private Equity, successively working as managing director, chairperson of management committee and vice-president (presiding over the work) (副總經理(主持工作)).

From March 2019 to April 2022, Ms. Zhang was a director of Bloomage Biotechnology Corporation Limited (華熙生物科技股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 688363)); from March 2020 to May 2023, Ms. Zhang was a director of Nanjing Vazyme Biotech Co., Ltd. (南京諾唯贊生物科技股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 688105)); from September 2020 to August 2023, Ms. Zhang was a director of Shanghai United Imaging Healthcare Co., Ltd. (上海聯影醫療科技股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 688271)); and since November 2022, Ms. Zhang has been a non-executive director of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (百奧賽圖(北京)醫藥科技股份有限公司) (a company listed on the Main Board of the Stock Exchange (stock code: 02315)).

Ms. Zhang will enter into a letter of appointment with the Company as a non-executive Director for a term commencing from 12 January 2024 to 31 December 2024, and she will be subject to rotation and re-election at general meeting of the Company in accordance with the bye-laws of the Company. Ms. Zhang will not be entitled to any remuneration from the Company in her capacity as a non-executive Director.

Save as disclosed above, as at the date of this announcement, Ms. Zhang (i) does not hold any other position with the Company or other members of the Group; (ii) did not hold any other directorship in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; and (iii) does not hold any other major appointment or professional qualification.

As at the date of this announcement, Ms. Zhang (i) does not have any relationship with any Directors, senior management, substantial or controlling Shareholders (having the meanings ascribed to them in the Listing Rules); and (ii) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Ms. Zhang that need to be brought to the attention of the Shareholders.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board announces that with effect from 12 January 2024:

- (i) Mr. Yu Xuezhong, an independent non-executive Director, has resigned as a member of the audit committee of the Board (“**Audit Committee**”);
- (ii) Dr. Xu Weiguo, an independent non-executive Director, has resigned as a member of the remuneration committee of the Board (“**Remuneration Committee**”);
- (iii) Mr. Liu Yang, a non-executive Director, has been appointed as a member of each of the Audit Committee and the Remuneration Committee;
- (iv) Mr. Chan Wai Kan, an independent non-executive Director, has been appointed as a member of the Remuneration Committee;

- (v) Mr. Cheung Ka Ming, an independent non-executive Director, has been appointed as a member of the Audit Committee; and
- (vi) Mr. Tsui Wing Cheong Sammy, an independent non-executive Director, has been appointed as a member of the nomination committee of the Board (“**Nomination Committee**”).

The Board would like to express its sincere gratitude to Mr. Hou for his invaluable contribution to the Company during his tenure of office and its warmest welcome to Ms. Zhang on her new appointment.

By Order of the Board
Town Health International Medical Group Limited
Kwok Chung On
Company Secretary

Hong Kong, 12 January 2024

As at the date of this announcement, the executive Directors are Mr. Choi Ka Tsan Karson (Chairman and Chief Executive Officer), Dr. Fok Siu Wing Dominic, Ms. Zhang Xiaoxue and Mr. Liu Shiyin; the non-executive Directors are Ms. Lee Wai Ling Linda, Ms. Lau Suk Hing Clara, Mr. Liu Yang and Ms. Zhang Leidi; and the independent non-executive Directors are Mr. Yu Xuezhong, Dr. Xu Weiguo, Mr. Han Wenxin, Mr. Chan Wai Kan, Mr. Cheung Ka Ming and Mr. Tsui Wing Cheong Sammy.